Semmelweis Repozitórium
→
MTMT-ben szereplő publikációk
→
MTMT-ben szereplő publikációk Tallózás szerző szerint

MTMT-ben szereplő publikációk tallózása szerző szerint "Santarpia L"

1-7 / 7

Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes

Győrffy, Balázs; Bottai G; Fleischer T; Munkácsy, Gyöngyi; Budczies J; Paladini L; Boressen-Dale AL; Kristensen VN; Santarpia L (2016)
A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer

Menyhart, Otilia; Santarpia L; Győrffy, Balázs (2015)

The introduction of trastuzumab for anti-HER2 therapy dramatically changed the clinical outcome for HER2 (ERBB2, neu) positive breast cancer patients. Today, patients eligible for trastuzumab are selected using HER2 ...
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients

Bottai G; Raschioni C; Székely, Borbála; Di Tommaso L; Szász, Attila Marcell; Losurdo A; Győrffy, Balázs; Ács, Balázs; Torrisi R; Karachaliou N; Tőkés, Tímea; Caruso M; Kulka, Janina; Roncalli M; Santoro A; Mantovani A; Rosell R; Reis-Filho JS; Santarpia L (2016)

A subgroup of triple-negative breast cancer (TNBC) shows epithelial-to-mesenchymal transition (EMT) features, which are sustained by the interaction between cancer cells and tumor-associated macrophages (TAMs). In this ...
Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer

Santarpia L; Bottai G; Kelly CM; Győrffy, Balázs; Székely, Borbála; Pusztai L (2016)

: Advances in DNA and RNA sequencing revealed substantially greater genomic complexity in breast cancer than simple models of a few driver mutations would suggest. Only very few, recurrent mutations or copy-number variations ...
Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer

Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy, Balázs; Raschioni C; Pusztai L; Calin GA; Santarpia L (2017)

MicroRNAs (miRNAs) simultaneously modulate different oncogenic networks, establishing a dynamic system of gene expression and pathway regulation. In this study, we analyzed global miRNA and messenger RNA (mRNA) expression ...
miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer

Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy, Balázs; Santarpia L; Pusztai L; Saltzman WM; Slack FJ (2016)

Triple-negative breast cancer (TNBC) is an aggressive subtype with no clinically proven biologically targeted treatment options. The molecular heterogeneity of TNBC and lack of high frequency driver mutations other than ...
miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients

Lánczky A; Nagy, Ádám; Bottai G; Munkácsy, Gyöngyi; Szabó, András; Santarpia L; Győrffy, Balázs (2016)

PURPOSE: The proper validation of prognostic biomarkers is an important clinical issue in breast cancer research. MicroRNAs (miRNAs) have emerged as a new class of promising breast cancer biomarkers. In the present work, ...

1-7 / 7

Keresés

Összetett keresés

Tallózás

Teljes repozitórumban
Ebben a kategóriában

Hozzáférésem

Bejelentkezés

MTMT-ben szereplő publikációk tallózása szerző szerint "Santarpia L"

DSpace/Manakin Repository

MTMT-ben szereplő publikációk tallózása szerző szerint "Santarpia L"

Keresés

Tallózás

Teljes repozitórumban

Ebben a kategóriában

Hozzáférésem